Recombinant human erythropoietin treatment improves platelet function in uremic patients
- 1 September 1992
- journal article
- Published by Elsevier in Kidney International
- Vol. 42 (3) , 668-672
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effects of Recombinant Human Erythropoietin and Correction of Anemia on Platelet Function in Hemodialysis PatientsNephron, 1991
- BLEEDING IN RENAL FAILUREThe Lancet, 1988
- IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETINThe Lancet, 1987
- Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis.BMJ, 1987
- Correction of the Anemia of End-Stage Renal Disease with Recombinant Human ErythropoietinNew England Journal of Medicine, 1987
- EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT DNA ON THE ANAEMIA OF PATIENTS MAINTAINED BY CHRONIC HAEMODIALYSISThe Lancet, 1986
- Defective platelet adhesion on vessel subendothelium in uremic patientsBlood, 1986
- Low haematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusionsBritish Journal of Haematology, 1985
- URAEMIC BLEEDING: ROLE OF ANAEMIA AND BENEFICIAL EFFECT OF RED CELL TRANSFUSIONSThe Lancet, 1982
- Bleeding time in Uremia: A useful test to assess clinical bleedingAmerican Journal of Hematology, 1979